Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021

Heather Whitaker*, Suzanne Elgohari, Cathy Rowe, Ashley Otter, Timothy Brooks, Ezra Linley, Iain Hayden, Sonia Ribeiro, Jacqueline Hewson, Anissa Lakhani, Eleanor Clarke, Camille Tsang, Colin Campbell, Mary Ramsay, Kevin Brown, Gayatri Amirthalingam

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

1 Citation (Scopus)


The COVID-19 vaccination programme commenced in England on 8th December 2020 primarily based on age; by 7th March 2021 approximately 93% of the English population aged 70+ years had received at least 1 dose of either the Pfizer BioNTech or AstraZeneca vaccines. Using a nucleoprotein assay that detects antibodies following natural infection only and a spike assay that detects infection and vaccine-induced responses, we aim to describe the impact of vaccination on SARS-CoV-2 antibody prevalence in English blood donors.

Original languageEnglish
Pages (from-to)269-271
Number of pages3
JournalJournal of Infection
Issue number2
Publication statusPublished - Aug 2021

Bibliographical note

Funding Information:
We are grateful to Su Brailsford and colleagues in NHS Blood and Transplant for the support and collaboration on this work.

Publisher Copyright:
© 2021


  • Antibodies
  • Blood Donors
  • COVID-19
  • COVID-19 Serological Testing
  • COVID-19 vaccines
  • SARS-CoV-2
  • Surveys


Dive into the research topics of 'Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021'. Together they form a unique fingerprint.

Cite this